Results 91 to 100 of about 214,611 (264)

Immediate Growth Control in Response to Boiling Histotripsy is Prognostic for Intratumoral Immune Activation

Advanced Science, EarlyView.
Boiling Histrotripsy (BH), a mechanical form of focused ultrasound (FUS), allows for non‐invasive and non‐ionizing tissue destruction. Utilizing a BH treatment protocol that yielded bifurcating primary tumor growth responses, we found that immediate BH‐induced tumor growth control identifies tumors with acute reductions in antigen‐presenting cells (APC)
Lydia E. Kitelinger, Matthew R. DeWitt, Carly M. Van Wagoner, Claire A. Conarroe, Charles C. Funk, Aaron B. Streit, AeRyon Kim, Richard J. Price, Timothy N. J. Bullock   +8 more
wiley   +1 more source

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition

OncoImmunology, 2017
Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies.
Takuya Osada, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, Hongtao Guo, Xiao-Yi Yang, Cong-Xiao Liu, Kensuke Kaneko, Gloria Broadwater, H. Kim Lyerly   +12 more
doaj   +1 more source

Characterizing individual anti-Her2 modules and the bi-modular anti-Her2-dCK fusion proteins.

, 2016
(A) Schematic of the ELISA assay used to evaluate the binding of the affinity reagents to the ectodomain IV of the Her2 receptor. (B) Binding of reagents to the ectodomain IV of Her2 receptor was measured by incubating 50 nM of reagents with 20 nM of ...
Arnon Lavie (307968), Ying Su (206940), Sujatha P. Koduvayur (524509), Brian K. Kay (524513)   +3 more
core   +1 more source

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas [PDF]

, 2005
INTRODUCTION: ScFv(FRP5)-ETA is a recombinant antibody toxin with binding specificity for ErbB2 (HER2). It consists of an N-terminal single-chain antibody fragment (scFv), genetically linked to truncated Pseudomonas exotoxin A (ETA).
Wels, Winfried, Sebastian Harder, Sibylle Loibl, Christian Cimpoiasu, Akin Atmaca, Cimpoiasu, C, Elke Jäger, Alexander Knuth, Dirk Jäger, Minckwitz, Gunter von, Neumann, A M, Harder, S, Cimpoiasu, Christian, Antje Neumann, Hövelmann, S, Winfried S Wels, Atmaca, Akin, Knuth, Alexander, Sascha Hövelmann, Abera, A, Abera, Aklil, Maurer, Alexander B., Gunter von Minckwitz, Aklil Abera, Al-Batran, S E, Knuth, A L, Loibl, S G, Hövelmann, Sascha, Jäger, Elke, Jäger, Dirk, Salah-Eddin Al-Batran, Alexander B Maurer, Loibl, Sibylle, Maurer, A B, Manfred Kaufmann, Wels, W S, von Minckwitz, G, Neumann, Antje, Jäger, D, Jäger, E, Atmaca, A, Kaufmann, M, Batran, Salah-Eddin al-, Kaufmann, Manfred, Harder, Sebastian   +44 more
core   +2 more sources

EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple‐Negative Breast Cancer Progression

Advanced Science, EarlyView.
Endothelin receptor type A (EDNRA) and the Hippo/YAP pathway form a self‐reinforcing loop that sustains triple‐negative breast cancer. EDNRA activates YAP through Gαq/11–Rho/ROCK–LATS signaling, while YAP/TEAD4 reciprocally drives EDNRA transcription.
Zehao Hong, Boyang Li, Jiahui Xu, Ruonan Lin, Jinghao Pan, Chenlu Fang, Boxiang Zhang, Lucy Yue Lau, Richard J. Aldridge, Elizabeth A. Whitmore, Yi Chen   +10 more
wiley   +1 more source

Intratumoral Hypoxia Triggers Mitochondrial BHLHE40 ROS Sensing Pathway to Promote Radioresistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Hypoxia triggers a dual mechanism for BHLHE40 upregulation: reactive oxygen species (ROS)‐dependent post‐translational modification and hypoxia‐inducible factor (HIF)‐dependent transcriptional activation. Under hypoxic conditions, mitochondrial BHLHE40 accumulates and senses ROS via cysteine thiol oxidation and disulfide‐linked homodimer formation ...
Jia Liu, Ziliang Nie, Xi Chen, Guangyu Ji, Yajing Zhang, Zhiqun Zhao, Yuhong Zhang, Xinlong Du, Zhenzhen Zhou, Jiayi Li, Yaozong Yang, Fengqi Sun, Zhibo Yan, Haiquan Lu   +13 more
wiley   +1 more source

Correlation of HER2 levels expression through HER2 mRNA PCR vs immunohistochemistry (IHC) in hormone receptor positive (HR+)/HER2 negative (HER2−) early breast cancer

Purpose To evaluate the correlation between HER2 expression levels measured by HER2 mRNA using Oncotype DX and by immunohistochemistry (IHC) in hormone receptor-positive (HR+) and HER2-negative (HER2−) early breast cancer.
Díaz Del Arco, Cristina, López de Sá, Alfonso, Moreno Antón, Fernando, García Sáenz, José Ángel   +3 more
core   +1 more source

Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy

Advanced Science, EarlyView.
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier, Megane Grah Kple, Julen Ariztia, Marion Leroux, Mathieu Moreau, Michael Claron, Maxime Cheveau, Adam Laouafa, Agnieszka Kownacka, Camille Petitot, John Simonet, Alexandre M. M. Dias, Sophie Poty, Charles Truillet, Bertrand Collin, Alexandra Oudot, Franck Denat   +16 more
wiley   +1 more source

HER2-Positive Breast Cancer.

, 2018
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs.
McCann, Kelly., Hurvitz, Sara.
core  

Nanoparticle‐Mediated TIPE1 mRNA Delivery Enhances Paclitaxel Sensitivity in Triple‐Negative Breast Cancer by Modulating RAB7A Ubiquitination‐Associated Stability and Autophagy

Advanced Science, EarlyView.
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu, Qishuai Chen, Yan Ma, Yang Liu, Xianing Dong, Wenjuan Wei, Jianxin Du, Shusheng Qiu, Maojin Tian, Peiqing Zhao   +9 more
wiley   +1 more source